Showing 20,101 - 20,120 results of 20,793 for search '"Therapy"', query time: 0.12s Refine Results
  1. 20101

    Expression analysis of transforming growth factor beta (TGF-β) in oral squamous cell carcinoma by Arun Ganesh, P.P. Ashikha Shirin Usman, Ameya K.P., Priya Thomas, Dhanraj M. Ganapathy, Durairaj Sekar

    Published 2024-03-01
    “…Although much progress has been made to control OSCC in recent years, therapies for OSCC remain challenging. Interestingly, transforming growth factor β (TGF-β) plays an important role in the extracellular microenvironment and different cellular processes like migration, proliferation, etc. …”
    Get full text
    Article
  2. 20102

    An injectable, expandable polyacrylamide cryogel decreases blood loss and improves survival in a porcine model of junctional hemorrhage by Al-Murtadha Al-Gahmi, Syed Muntazir Andrabi, S. M. Shatil Shahriar, Carlos P. Jara, Jingwei Xie, Mark A. Carlson

    Published 2025-02-01
    “…Abstract Uncontrolled hemorrhage, including junctional hemorrhage, is a leading cause of preventable death in military trauma. Effective therapies are urgently needed to stabilize patients and prevent further blood loss. …”
    Get full text
    Article
  3. 20103

    Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region by Geetika Sharma, Shilpi More, Saroj Rajput, Nimisha Sharma, Sonu Choudhary, Tathagata Chatterjee

    Published 2024-12-01
    “…Objective: The objective is to understand underlying mechanism in AIHAs, and usage of targeted therapies to modulate specific components of the immune response. …”
    Get full text
    Article
  4. 20104

    Metabolomic profiling of saliva from cystic fibrosis patients by M. Caterino, M. Costanzo, A. Castaldo, P. Iacotucci, V. Carnovale, M. Ruoppolo, M. Gelzo, G. Castaldo

    Published 2025-01-01
    “…Abstract The development of targeted therapies that correct the effect of mutations in patients with cystic fibrosis (CF) and the relevant heterogeneity of the clinical expression of the disease require biomarkers correlated to the severity of the disease useful for monitoring the therapeutic effects. …”
    Get full text
    Article
  5. 20105

    Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib by Paweł Robak, Edyta Węgłowska, Izabela Dróżdż, Damian Mikulski, Dariusz Jarych, Magdalena Ferlińska, Ewa Wawrzyniak, Małgorzata Misiewicz, Piotr Smolewski, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak

    Published 2020-01-01
    “…Patients who demonstrated CR or PR after bortezomib-based therapies longer than six months after treatment discontinuation were designated bortezomib sensitive. …”
    Get full text
    Article
  6. 20106

    Flunarizine as a Candidate for Drug Repurposing Against Human Pathogenic Mammarenaviruses by Chukwudi A. Ofodile, Ikemefuna C. Uzochukwu, Fortunatus C. Ezebuo, InnocentMary Ejiofor, Mercy Adebola, Innocent Okpoli, Beatrice Cubitt, Haydar Witwit, Chetachi B. Okwuanaso, Ngozi Onyemelukwe, Juan Carlos de la Torre

    Published 2025-01-01
    “…Currently, no vaccines or therapies are specifically licensed to prevent or treat LF, hence the significance of developing therapeutics against the mammarenavirus Lassa virus (LASV), the causative agent of LF. …”
    Get full text
    Article
  7. 20107

    Targeting murine metastatic cancers with cholera toxin A1-adjuvanted peptide vaccines by Sanchari Paul, Mustafa Kaya, Olivia Johnsson, Hanna Grauers Wiktorin, Andreas Törnell, Mohammad Arabpour, Kristoffer Hellstrand, Anna Martner

    Published 2025-12-01
    “…Cholera toxin-based adjuvants have shown efficacy in vaccines for infectious diseases, but their role in cancer vaccine therapies remains to be elucidated. Here, we explored the potential of cholera toxin A1 (CTA1)-based adjuvants to boost anti-tumor T cell responses and protect against metastasis. …”
    Get full text
    Article
  8. 20108

    Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern EuropeansResearch in context by Ben Krause-Kyora, Nicolas Antonio da Silva, Elif Kaplan, Daniel Kolbe, Inken Wohlers, Hauke Busch, David Ellinghaus, Amke Caliebe, Efe Sezgin, Almut Nebel, Stefan Schreiber, Sabine Schade-Lindig, Joachim Wahl, Carola Berszin, Michael Francken, Irina Görner, Kerstin Schierhold, Joachim Pechtl, Gisela Grupe, Johannes Müller

    Published 2025-03-01
    “…The adaptively evolved function of the variant likely contributes to the high efficacy and low side-effects of modern IL-23 neutralisation therapies for chronic inflammatory diseases. Funding: German Research Foundation (EXC 2167 390884018 and EXC 2150 390870439).…”
    Get full text
    Article
  9. 20109

    Therapeutic Potential of Stem Cells in Follicle Regeneration by Agnieszka Owczarczyk-Saczonek, Magdalena Krajewska-Włodarczyk, Anna Kruszewska, Łukasz Banasiak, Waldemar Placek, Wojciech Maksymowicz, Joanna Wojtkiewicz

    Published 2018-01-01
    “…The ubiquity of alopecia provides an encouragement to seek new, more effective therapies aimed at hair follicle regeneration and neoregeneration. …”
    Get full text
    Article
  10. 20110

    Integrated bioinformatics analysis identifies ALDH18A1 as a prognostic hub gene in glutamine metabolism in lung adenocarcinoma by Hao Ren, Deng-Feng Ge, Zi-Chen Yang, Zhen-Ting Cheng, Shou-Xiang Zhao, Bin Zhang

    Published 2025-01-01
    “…Abstract Glutamine metabolism is pivotal in cancer biology, profoundly influencing tumor growth, proliferation, and resistance to therapies. Cancer cells often exhibit an elevated dependence on glutamine for essential functions such as energy production, biosynthesis of macromolecules, and maintenance of redox balance. …”
    Get full text
    Article
  11. 20111
  12. 20112

    PARP Inhibitors in the Treatment of Ovarian Cancer by Andrzej Paweł Zuzak, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska

    Published 2025-02-01
    “…These inhibitors have been validated in multiple clinical trials, underscoring their robustness and effectiveness. Combination therapies, such as olaparib with bevacizumab, further enhance therapeutic outcomes, showcasing the potential for synergistic effects. …”
    Get full text
    Article
  13. 20113

    Effect of Nebulized Morphine on Dyspnea of Mustard Gas-Exposed Patients: A Double-Blind Randomized Clinical Trial Study by Majid Shohrati, Mostafa Ghanei, Asghar Amini Harandi, Soniya Foroghi, Ali Amini Harandi

    Published 2012-01-01
    “…Dyspnea is one of the main complaints in a group of COPD patients due to exposure to sulfur mustard (SM) and is refractory to conventional therapies. We designed this study to evaluate effectiveness of nebulized morphine in such patients. …”
    Get full text
    Article
  14. 20114

    Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions by Stefania Kalampokini, Anouck Becker, Klaus Fassbender, Epameinondas Lyros, Marcus M. Unger

    Published 2019-01-01
    “…Diet targets mediators of inflammation with various mechanisms and combined with dopaminergic treatment can exert various beneficial effects in PD. Food-based therapies may favorably modulate gut microbiota composition and enhance the intestinal epithelial integrity or decrease the proinflammatory response by direct effects on immune cells. …”
    Get full text
    Article
  15. 20115

    Black Tea May Be a Prospective Adjunct for Calcium Supplementation to Prevent Early Menopausal Bone Loss in a Rat Model of Osteoporosis by Asankur Sekhar Das, Maitrayee Banerjee, Dolan Das, Sandip Mukherjee, Chandan Mitra

    Published 2013-01-01
    “…This study suggests that simultaneous use of BTE is promising as a prospective candidate for adjunctive therapies for calcium supplementation in the early stage of menopausal bone changes.…”
    Get full text
    Article
  16. 20116

    Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration by Lewis E. Fry, Lauren Major, Ahmed Salman, Lucy A. McDermott, Jun Yang, Andrew J. King, Michelle E. McClements, Robert E. MacLaren

    Published 2025-02-01
    “…These results support the development of transcriptome targeting gene editing therapies for retinal disease.…”
    Get full text
    Article
  17. 20117

    Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia by David Olivares-Berjaga, Albert Martínez-Pinteño, Natalia Rodríguez, Sergi Mas, Constanza Morén, Eduard Parellada, Patricia Gassó

    Published 2025-01-01
    “…The neurodevelopmental glutamate hypothesis of SZ has opened new avenues in the development of drugs targeting the glutamatergic system. One of these new therapies involves the positive allosteric modulators (PAMs) of metabotropic glutamate receptors, mainly types 2/3 (mGluR2/3). mGluR2/3 PAMs are selective for the receptor, present high tolerability and can modulate the activity of the receptor for long periods. …”
    Get full text
    Article
  18. 20118

    Research Progress on Natural Products That Regulate miRNAs in the Treatment of Osteosarcoma by Lin Wang, Xinyu Liu, Haoze Lv, Han Zhang, Rimei Lin, Shan Xu, Chaojing Zhang, Shilei Lou, Zhidong Qiu, Cong Sun, Ning Cui

    Published 2025-01-01
    “…Currently, research on miRNAs has become a major focus in developing cancer therapies. Osteosarcoma, a malignant neoplasm predominantly occurring during adolescence and later in life, is characterized by a high propensity for metastasis. …”
    Get full text
    Article
  19. 20119

    THE IMPACT OF ADDING RAPHANUS SATIVUS SEEDS TO THE DIET OF BROILER BREEDERS ON EGG PRODUCTION AND QUALITY, HATCHABILITY, AND PHYSIOLOGICAL TRAITS by S. M. Abdulateef, Z. J. M. Saed, Dr.Thafer Mohammed, A. B. Mohammed

    Published 2024-12-01
    “…The T4 treatment was more effective than the cellular therapies producing better egg weight and hatchability. …”
    Get full text
    Article
  20. 20120

    Efectividad de las intervenciones de mente-cuerpo en pacientes oncológicos al final de la vida: ¿qué dice la literatura? by Yusley Katerine Pabón-Salazar, Daniela Burbano Mellizo, Angela Portilla Ceballos, Ana Sofía Perdomo Moncayo, Ana Maritza Benavides Toro

    Published 2023-07-01
    “…Se usó el algoritmo de búsqueda (((((cancer) OR (malignant tumor)) OR (carcinoma)) OR (neoplasms)) OR (advanced cancer)) AND (mind.body therapies) obteniendo 2347. Resultados: Se evidenció que la intervención de mente-cuerpo más usada fue la psicoterapia, que es aquella terapia donde se realiza un diálogo entre el paciente y el profesional, esta fue empleada en 5 estudios y en todos mostró resultados positivos en: ansiedad, depresión, bienestar espiritual, esperanza, malestar psicológico, calidad de vida, gravedad de los síntomas y fatiga. …”
    Get full text
    Article